Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.
Zhitao ChenTielong WangChuanbao ChenXitao HongJia YuYihao MaYiwen GuoChangjun HuangXiaoshun HeWeiqiang JuMaogen ChenPublished in: Journal of oncology (2021)
Pretransplant CTC status can guide the administration of pretransplant RFA in HCC patients which can improve PFS in CTC-positive HCC patients.